IL164099A0 - Use of interleukin-19 to treat cervical cancer - Google Patents
Use of interleukin-19 to treat cervical cancerInfo
- Publication number
- IL164099A0 IL164099A0 IL16409903A IL16409903A IL164099A0 IL 164099 A0 IL164099 A0 IL 164099A0 IL 16409903 A IL16409903 A IL 16409903A IL 16409903 A IL16409903 A IL 16409903A IL 164099 A0 IL164099 A0 IL 164099A0
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- cervical cancer
- treat cervical
- treat
- cancer
- Prior art date
Links
- 206010008342 Cervix carcinoma Diseases 0.000 title 1
- 102000001933 Interleukin-19 Human genes 0.000 title 1
- 108050009288 Interleukin-19 Proteins 0.000 title 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 title 1
- 201000010881 cervical cancer Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37162002P | 2002-04-10 | 2002-04-10 | |
| PCT/US2003/010507 WO2003087307A2 (en) | 2002-04-10 | 2003-04-08 | Use of interleukin-19 to treat cervical cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL164099A0 true IL164099A0 (en) | 2005-12-18 |
Family
ID=29250710
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16409903A IL164099A0 (en) | 2002-04-10 | 2003-04-08 | Use of interleukin-19 to treat cervical cancer |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7247444B2 (xx) |
| EP (1) | EP1492560A4 (xx) |
| JP (1) | JP2005529113A (xx) |
| AU (1) | AU2003223481A1 (xx) |
| CA (1) | CA2479519A1 (xx) |
| IL (1) | IL164099A0 (xx) |
| WO (1) | WO2003087307A2 (xx) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003223481A1 (en) | 2002-04-10 | 2003-10-27 | Zymogenetics, Inc. | Use of interleukin-19 to treat cervical cancer |
| JP2005529101A (ja) | 2002-04-11 | 2005-09-29 | ザイモジェネティクス インコーポレイティッド | 卵巣癌を治療するためのインターロイキン−19の使用法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5965296A (en) | 1995-05-31 | 1996-12-18 | Regents Of The University Of Minnesota | Recombinant polypeptide cytotoxins for cancer treatment |
| AU3386597A (en) * | 1996-06-11 | 1998-01-07 | Advanced Research And Technology Institute, Inc. | Methods and compositions for the use of apurinic/apyrimidinic endonucleases |
| US5985614A (en) * | 1996-08-30 | 1999-11-16 | Human Genome Sciences, Inc. | Polynucleotides encoding interleukin-19 |
| US20020072089A1 (en) * | 1999-11-23 | 2002-06-13 | Holtzman Douglas A. | Novel ITALY, Lor-2, STRIFE, TRASH, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor |
| JP4768916B2 (ja) * | 1998-09-15 | 2011-09-07 | ユニバーシティ オブ ピッツバーグ オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | サイトカイン発現が遺伝的に増強された抗原提示細胞のインサイチュ注入 |
| AU2003223481A1 (en) | 2002-04-10 | 2003-10-27 | Zymogenetics, Inc. | Use of interleukin-19 to treat cervical cancer |
| JP2005529101A (ja) * | 2002-04-11 | 2005-09-29 | ザイモジェネティクス インコーポレイティッド | 卵巣癌を治療するためのインターロイキン−19の使用法 |
| US20040076606A1 (en) | 2002-09-14 | 2004-04-22 | Ming-Shi Chang | Methods of modulating inflammation by administration of interleukin-19 and inhibitors of IL-19 binding |
-
2003
- 2003-04-08 AU AU2003223481A patent/AU2003223481A1/en not_active Abandoned
- 2003-04-08 IL IL16409903A patent/IL164099A0/xx unknown
- 2003-04-08 JP JP2003584251A patent/JP2005529113A/ja not_active Withdrawn
- 2003-04-08 US US10/409,405 patent/US7247444B2/en not_active Expired - Fee Related
- 2003-04-08 WO PCT/US2003/010507 patent/WO2003087307A2/en not_active Ceased
- 2003-04-08 EP EP03719611A patent/EP1492560A4/en not_active Withdrawn
- 2003-04-08 CA CA002479519A patent/CA2479519A1/en not_active Abandoned
-
2007
- 2007-06-19 US US11/765,289 patent/US20070269407A1/en not_active Abandoned
-
2009
- 2009-07-24 US US12/508,812 patent/US20090285778A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1492560A2 (en) | 2005-01-05 |
| WO2003087307A3 (en) | 2004-06-10 |
| WO2003087307A2 (en) | 2003-10-23 |
| EP1492560A4 (en) | 2007-05-30 |
| AU2003223481A1 (en) | 2003-10-27 |
| US20070269407A1 (en) | 2007-11-22 |
| US20090285778A1 (en) | 2009-11-19 |
| US7247444B2 (en) | 2007-07-24 |
| US20030219379A1 (en) | 2003-11-27 |
| CA2479519A1 (en) | 2003-10-23 |
| JP2005529113A (ja) | 2005-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2003239568A1 (en) | Pyrrolotriazinone compounds and their use to treat diseases | |
| IL164599A0 (en) | Combination therapy for the treatment of cancer | |
| IL166280A0 (en) | Treatment of TNF? related disorders | |
| HUP0500165A2 (en) | Chalcone derivatives and their use to treat diseases | |
| GB0324761D0 (en) | Use of compounds in therapy | |
| ZA200410409B (en) | Use of thio-oxindole derivatives in treatment of hormonerelated conditions | |
| AU2003212634A8 (en) | Compounds useful in the treatment of cancer | |
| GB0305150D0 (en) | Use of therapeutic compounds | |
| IL160928A0 (en) | Use of histamine to treat liver disease | |
| HRP20030874A2 (en) | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases | |
| EP1373221A4 (en) | NOVEL CYANO SUBSTITUTED DIHYDROPYRIMIDINE COMPOUNDS AND THERATEUTIC USE THEREOF | |
| AU2003295336A1 (en) | Use of etodoclac to treat hyperplasia | |
| GB0320238D0 (en) | Treatment of disease | |
| IL166016A0 (en) | Topical treatment of skin diseases | |
| GB0213869D0 (en) | The treatment of pain | |
| GB0211295D0 (en) | Treatment of pain | |
| IL164214A0 (en) | Use of interleukin-24 to treat ovarian cancer | |
| AU2003302822A8 (en) | Antibodies to treat cancer | |
| LT1496918T (lt) | Natrio meta-arsenito naudojimas navikams gydyti | |
| AU2003241346A8 (en) | Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer | |
| AP2004003174A0 (en) | Treatment of water | |
| GB0218798D0 (en) | Improvements to determination of ovulation | |
| GB0210741D0 (en) | Methods of therapy | |
| GB0101146D0 (en) | Treatment of skin conditions | |
| IL164099A0 (en) | Use of interleukin-19 to treat cervical cancer |